HC Wainwright Reiterates Buy Rating for Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $6.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 140.00% from the company’s previous close.

Lyell Immunopharma Stock Performance

Lyell Immunopharma stock opened at $2.50 on Tuesday. The stock has a 50-day simple moving average of $2.33 and a 200-day simple moving average of $2.09. The company has a market capitalization of $637.35 million, a P/E ratio of -2.69 and a beta of -0.54. Lyell Immunopharma has a fifty-two week low of $1.32 and a fifty-two week high of $3.97.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Wednesday, February 28th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. As a group, analysts forecast that Lyell Immunopharma will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC acquired a new position in Lyell Immunopharma in the 4th quarter valued at $31,000. RPO LLC acquired a new position in shares of Lyell Immunopharma during the fourth quarter worth about $38,000. Public Employees Retirement System of Ohio raised its holdings in Lyell Immunopharma by 109.7% during the third quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock worth $40,000 after purchasing an additional 14,229 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Lyell Immunopharma by 352.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company’s stock valued at $57,000 after purchasing an additional 22,701 shares during the period. Finally, Simplicity Wealth LLC purchased a new stake in Lyell Immunopharma in the 1st quarter valued at approximately $58,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.